Blog Details

Lilly’s revenue soars 48%, driven by demand of its GLP-1s

Lilly’s revenue soars 48%, driven by demand of its GLP-1s

Its sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.

Read the full article on MarketWatch ?

Start Trading Today

Join thousands of traders and investors. Discover how specific trading strategies work — and get started with your investment journey.